Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NutriLock is a non-antibiotic catheter lock solution developed by Transcutan (TauroLock GmbH) specifically for patients receiving parenteral nutrition. It is designed to prevent catheter-related bloodstream infections (CRBSI) and maintain catheter patency by preventing occlusions. The solution contains taurolidine, a broad-spectrum antimicrobial agent that prevents biofilm formation by reacting with bacterial cell wall components, and 4% citrate, which serves as an anticoagulant by chelating calcium. NutriLock is particularly useful in home parenteral nutrition (HPN) settings where it provides a safe alternative to heparin, avoiding risks such as heparin-induced thrombocytopenia. It is intended for use in the dead space of central venous catheters between treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NutriLock.